Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
Rhea-AI Summary
INmune Bio (NASDAQ: INMB) announced a peer-reviewed overview on mesenchymal stromal cell (MSC) therapies published in Cytotherapy, titled “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions.”
Lead scientist on INmune’s CORDStrom™ R&D, Dr Nikita M. Patel, was one of the senior authors on an invitation-only working party that reviewed current knowledge and gaps for MSC development. Topics included systemic delivery, local/depot delivery (the CORDStrom™ approach), and in vivo persistence. The company said it is initially developing CORDStrom™ for RDEB and expects to file a BLA and MAA in 2026.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Up
INMB gained 7.1% while close peers showed mixed moves: PDSB up 3.18%, VTVT up 4.63%, GNTA and PYPD down and JUNS flat. Only one momentum-scanner peer (CUE, up 13.2%) appeared, suggesting INMB’s action is more stock-specific than broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Clinical data update | Positive | -10.1% | Phase 2 grey-matter MRI data from MINDFuL in high-inflammation Alzheimer’s. |
| Nov 18 | Conference presentations | Positive | +2.7% | Announcement of two scientific posters at the CTAD Alzheimer’s conference. |
| Oct 30 | Earnings and update | Neutral | -5.0% | Q3 2025 results with lower net loss, cash update, and multiple clinical milestones. |
| Oct 23 | Earnings preview | Neutral | +0.6% | Notice of upcoming Q3 2025 results call and webcast details. |
| Oct 14 | Conference participation | Positive | +2.2% | CEO participation on rare dermatologic disease panel discussing CORDStrom for RDEB. |
Recent INMB news with seemingly positive clinical or platform progress has sometimes met with negative or muted price reactions, particularly the Alzheimer’s imaging update, while conference and communication events have more often aligned with modest gains.
Over the last few months, INMB has reported multiple clinical and corporate milestones. Q3 2025 results showed a net loss of $6.5M vs $12.1M a year earlier and cash of $27.7M with ~26.6M shares outstanding as of Oct 30, 2025. The company advanced CORDStrom with pilot manufacturing and mid-2026 MAA plans, while XPro1595 and INKmune generated Phase 2 and CARE-PC data. An 8-K detailed shareholder-approved repricing of options on up to 5,511,000 shares to $1.50. Today’s article emphasizes the scientific underpinnings and future applications of the CORDStrom platform.
Market Pulse Summary
This announcement highlights peer-reviewed support for mesenchymal stromal cell therapies and INMB’s CORDStrom platform, including discussion of delivery approaches and in vivo persistence. Management reiterates plans to pursue BLA and MAA filings in 2026 for RDEB, tying into earlier updates on CORDStrom manufacturing progress. Investors may track how this scientific positioning complements prior clinical data and recent option repricing events while monitoring future regulatory and trial milestones.
Key Terms
mesenchymal stromal cell medical
AI-generated analysis. Not financial advice.
Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune’s CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was published in the peer-reviewed journal Cytotherapy. One of the lead authors of the paper was INmune Bio’s lead scientist for CORDStrom™ R&D, Dr Nikita M. Patel, M.Sci.,Ph.D.
The article, was the result of an invitation-only working party of basic, clinical and translational scientists working on MSCs and available on Cytotherapy’s website, reviews the current knowledge-base and critical gaps in order to formulate experimental questions designed to enhance development of MSC therapies such as the CORDStrom™ platform. These topics included systemic delivery of MSCs, local and/or depot-delivery (which is the method for the Company’s CORDStrom™ platform), and in vivo persistence.
“While CORDStrom™ is initially being developed for use in RDEB, in which we expect to file a BLA and MAA in 2026, publications such as this one provide important scientific background for future development of the CORDStrom™ platform. Stromal cell therapies are an important clinical advancement that may have significant impact in multiple indications including inflammation, immunomodulation, and wound healing,” said Dr. Mark Lowdell, INmune Bio CSO. “Nikita’s role within INmuneBio supports continued advancement in the knowledge base on MSCs. We believe her contributions as one of the senior authors to this article, and the insightful questions asked by the panel, will have an important impact on the development of the use of MSCs in general in addition to the ongoing development of our CORDStrom™ platform.”
About CORDStrom™
CORDStrom™ (pobistrocel) is a patent-pending cell medicine comprising aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion. The CORDStrom™ platform leverages, among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs as medicines to treat complex inflammatory, degenerative and autoimmune diseases. CORDStrom™ products are designed to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be produced affordably and with repeatable specification, independent of donor characteristics. While the first generation CORDStrom™ product is agnostic to disease indication, the platform enables creation of indication-specific products, which can be tuned for optimization of anti-inflammatory, immunomodulatory, wound healing, and other characteristics.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune dysfunction to fight disease. The Company’s pipeline include:
- CORDStrom™, an allogeneic mesenchymal stromal cell platform that recently completed a randomized, double-blinded study in recessive dystrophic epidermolysis bullosa.
- DN-TNF Platform (XPro™/XPro1595), for neuroinflammatory and neurodegenerative conditions.
- INKMune™, designed to prime natural killer cells (NK) to eliminate minimal residual disease in cancer.
For more information, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, the timing of key milestones, future plans or expectations for the development of all drugs in our portfolio and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ
What did INMB announce on December 5, 2025 about MSC research?
How does the Cytotherapy paper relate to INMB's CORDStrom™ platform?
What development timeline did INMB give for CORDStrom™ in RDEB?
Who from INMB contributed to the Cytotherapy publication?
Will the Cytotherapy review affect INMB's regulatory plans for INMB (NASDAQ: INMB)?
What scientific topics in the paper could influence INMB's clinical strategy for INMB (INMB)?
